Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMD14 | O00487 | 5/20 | 0.62 |
| ▸ | COPS5 | Q92905 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
| ▸ | CCR1 | P32246 | 2/20 | 0.61 |
| ▸ | CCR5 | P51681 | 2/20 | 0.61 |
| ▸ | CCR8 | P51685 | 2/20 | 0.61 |
| ▸ | PARP1 | P09874 | 2/20 | 0.58 |
| ▸ | SLC40A1 | Q9NP59 | 6/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | NFKBIA | P25963 | 1/20 | 0.41 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | STAMBP | O95630 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7376462 | 0.80 | PSMD14 (0.67) | PSMD14COPS5KDM4ECCR1CCR5 | |
| SCHEMBL2850764 | 0.78 | PSMD14 (0.65) | PSMD14COPS5KDM4ECCR1CCR5 | |
| SCHEMBL10238875 | 0.78 | PSMD14 (0.64) | PSMD14COPS5KDM4ECCR1CCR5 | |
| SCHEMBL29800848 | 0.77 | KDM4E (0.62) | PSMD14COPS5KDM4ECCR1CCR5 | |
| SCHEMBL6422325 | 0.77 | PSMD14 (0.62) | PSMD14COPS5KDM4ECCR1CCR5 | |
| SCHEMBL26314901 | 0.77 | KDM4E (0.62) | PSMD14COPS5KDM4ECCR1CCR5 | |
| SCHEMBL3718782 | 0.77 | KDM4E (0.62) | PSMD14COPS5KDM4ECCR1CCR5 | |
| SCHEMBL3067414 | 0.77 | PSMD14 (1.00) | PSMD14COPS5KDM4ECCR1CCR5 | |
| SCHEMBL26074213 | 0.77 | KDM4E (0.62) | PSMD14COPS5KDM4ECCR1CCR5 | |
| SCHEMBL1787225 | 0.77 | KDM4E (1.00) | PSMD14COPS5KDM4ECCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | PSMD14 3910/4885COPS5 3692/4885KDM4E 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.